Burosumab medicine supply for pediatric patients

Summary

Open tender for the supply of burosumab medicine (Crysvita) for pediatric patients with X-linked hypophosphatemic rickets. The contract covers burosumab injection solutions of 20 mg and 30 mg with active ingredient burosumab. The planned duration is 24 months and the estimated total contract amount is 618,313.75 EUR including VAT. Offers are evaluated on price only. The submission deadline is 23 October 2026 at 09:00 local time; Open Tender Event will take place in Košice. The procurement requires electronic invoicing and may be awarded as a framework agreement. Tender documents contain exclusion grounds and qualification requirements. The procurement is not EU-funded.